美国国家癌症数据库中ERBB2低表达乳腺癌的临床病理特征与预后
这项基于美国国家癌症数据库的回顾性队列研究纳入2010年1月1日至2019年12月31日诊断的1 136 016例ERBB2阴性浸润性乳腺癌患者,比较ERBB2低表达与ERBB2阴性乳腺癌的流行病学特征、预后及新辅助化疗反应。研究发现两组预后差异极小,ERBB2低表达与病理完全缓解率略低相关(aOR 0.89),仅在III期和IV期三阴性乳腺癌中总生存有轻微改善,不支持将ERBB2低表达乳腺癌列为独立疾病实体。
要点
- ERBB2低表达乳腺癌占ERBB2阴性浸润性乳腺癌的65.5%(743 770/1 136 016例)。
- ERBB2低表达组病理完全缓解率略低于ERBB2阴性组(aOR 0.89;95% CI 0.86-0.92;P < .001)。
- 仅III期和IV期三阴性乳腺癌中ERBB2低表达与总生存轻微改善相关,5年OS分别提高2.0%和0.4%。
核心结论
- 这项大规模回顾性队列分析发现ERBB2低表达与ERBB2阴性乳腺癌之间预后差异极小。
- 作者认为未来ERBB2低表达乳腺癌的结局将由靶向ERBB2的抗体药物偶联物驱动,而非低水平ERBB2表达相关的内在生物学差异。
- 这些发现不支持将ERBB2低表达乳腺癌归类为独特的疾病实体。
研究设计与样本
- 回顾性队列研究,使用美国国家癌症数据库。
- 纳入2010年1月1日至2019年12月31日诊断的1 136 016例ERBB2阴性浸润性乳腺癌患者,均有免疫组化结果。
- ERBB2低表达定义为免疫组化评分1+,或2+且原位杂交阴性。
- 数据分析时间为2021年11月1日至2022年11月30日。
- 暴露为标准临床实践治疗。
主要发现
- 共1 136 016例患者,平均(SD)年龄62.4(13.1)岁,女性占99.1%,非西班牙裔白人占78.6%。
- ERBB2阴性组392 246例(34.5%),ERBB2低表达组743 770例(65.5%)。
- ERBB2阴性组平均(SD)年龄62.1(13.2)岁,ERBB2低表达组62.5(13.0)岁。
- 雌激素受体表达越高,ERBB2低表达率越高(每增加10%,aOR 1.15)。
- 非西班牙裔白人ERBB2低表达率为66.1%,非西班牙裔黑人为62.8%,西班牙裔为61.0%;非西班牙裔黑人中的差异由三阴性乳腺癌比例及其他混杂因素介导。
关键数值与推荐
- 多因素分析中,ERBB2低表达组病理完全缓解率略低于ERBB2阴性组(aOR 0.89;95% CI 0.86-0.92;P < .001)。
- III期三阴性乳腺癌中,ERBB2低表达与总生存轻微改善相关(aHR 0.92;95% CI 0.89-0.96;P < .001),5年OS仅提高2.0%。
- IV期三阴性乳腺癌中,ERBB2低表达与总生存轻微改善相关(aHR 0.91;95% CI 0.87-0.96;P < .001),5年OS仅提高0.4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Given conflicting results regarding the prognosis of erb-b2 receptor tyrosine kinase 2 (ERBB2; formerly HER2 or HER2/neu)-low breast cancer, a large-scale, nationally applicable comparison of ERBB2-low vs ERBB2-negative breast cancer is needed. OBJECTIVE: To investigate whether ERBB2-low breast cancer is a clinically distinct subtype in terms of epidemiological characteristics, prognosis, and response to neoadjuvant chemotherapy. DESIGN/PARTICIPANTS/SETTING: This retrospective cohort study was conducted using the National Cancer Database, including 1 136 016 patients in the US diagnosed with invasive breast cancer from January 1, 2010, to December 31, 2019, who had ERBB2-negative disease and had immunohistochemistry results available. ERBB2-low tumors were classified as having an immunohistochemistry score of 1+, or 2+ with a negative in situ hybridization test. Data were analyzed from November 1, 2021, through November 30, 2022. EXPOSURES: Standard therapy according to routine clinical practice. MAIN OUTCOMES AND MEASURES: The primary outcomes were overall survival (OS), reported as adjusted hazard ratios (aHRs), and pathologic complete response, reported as adjusted odds ratios (aORs), for ERBB2-negative vs ERBB2-low breast cancer, controlling for age, sex, race and ethnicity, Charlson-Deyo Comorbidity Index score, treatment facility type, tumor grade, tumor histology, hormone receptor status, and cancer stage. RESULTS: The study identified 1 136 016 patients (mean [SD] age, 62.4 [13.1] years; 99.1% female; 78.6% non-Hispanic White), of whom 392 246 (34.5%) were diagnosed with ERBB2-negative and 743 770 (65.5%) with ERBB2-low breast cancer. The mean (SD) age of the ERBB2-negative group was 62.1 (13.2) years and 62.5 (13.0) years for the ERBB2-low group. Higher estrogen receptor expression was associated with increased rates of ERBB2-low disease (aOR, 1.15 per 10% increase). Compared with non-Hispanic White patients, of whom 66.1% were diagnosed with ERBB2-low breast cancer, fewer non-Hispanic Black (62.8%) and Hispanic (61.0%) patients had ERBB2-low disease, although in non-Hispanic Black patients this was mediated by differences in rates of triple-negative disease and other confounders. A slightly lower rate of pathologic complete response was seen in patients with ERBB2-low disease vs patients with ERBB2-negative disease on multivariable analysis (aOR, 0.89; 95% CI, 0.86-0.92; P < .001). ERBB2-low status was also associated with small improvements in OS for stage III (aHR, 0.92; 95% CI, 0.89-0.96; P < .001) and stage IV (aHR, 0.91; 95% CI, 0.87-0.96; P < .001) triple-negative breast cancer, although this amounted to only a 2.0% (stage III) and 0.4% (stage IV) increase in 5-year OS. CONCLUSIONS AND RELEVANCE: This large-scale retrospective cohort analysis found minimal prognostic differences between ERBB2-low and ERBB2-negative breast cancer. These findings suggest that, moving forward, outcomes in ERBB2-low breast cancer will be driven by ERBB2-directed antibody-drug conjugates, rather than intrinsic differences in biological characteristics associated with low-level ERBB2 expression. These findings do not support the classification of ERBB2-low breast cancer as a unique disease entity.
引用
- Peiffer DS, Zhao F, Chen N, et al. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023. PMID: 36821125. doi:10.1001/jamaoncol.2022.7476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。